GlaxoSmithKline is hoping for approval of quinolone antibiotic Factive (gemifloxacin) in time for the 2002 flu season, VP-New Product Development James Palmer tells Goldman Sachs conference. FDA issued a "not-approvable" letter for the drug in December (1"The Pink Sheet" Dec. 18, 2000, In Brief)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth